AstraZeneca, US6549022043

AstraZeneca stock holds after RBC starts coverage at GBP145

Published on 09/09/2026 at 14:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock drew RBC Capital's new GBP145 target on September 9, 2026. MarketBeat listed a USD 160.05 close, a USD 248.23 billion market cap and a 6.4 percent revenue rise.

Fotorealistisches Pharmaforschungslabor mit Wissenschaftlern in weißen Kitteln an Mikroskopen und Analysegeräten bei hellem klinischen Licht — AstraZeneca US6549022043 zeigt modernes Pharma Forschungslabor mit Wissenschaftlern an Mikroskopen und Analysegeräten, Illustration mit AI erstellt.

AstraZeneca stock (US6549022043) traded at USD 160.05 in New York on September 8, 2026, with a market capitalization of USD 248.23 billion and a 52-week range of USD 145.79 to USD 212.71. The move followed fresh broker coverage and left the shares 12.4 percent below their January 1, 2026 level, according to MarketBeat.

RBC opens a new call

According to TradingView on September 9, 2026, RBC started AstraZeneca with a GBP 145 target. MarketBeat also showed a moderate buy consensus, 14 buy ratings, two hold ratings and one sell rating, with an average target of USD 206.67.

That leaves the shares about 28.8 percent below the average target of USD 206.67, while the low end of the published target range sits at USD 198.00 and the high end at USD 216.00. For investors, the gap is still more important than the label.

Quarterly numbers stay central

MarketBeat said AstraZeneca's latest quarter, ending June 30, delivered revenue of USD 15.38 billion and earnings per share of USD 2.63, above the USD 2.50 consensus estimate by USD 0.13. Revenue rose 6.4 percent year on year, while net margin came in at 17.02 percent.

That mix matters because the stock is still valued at 23.92 times trailing earnings and 15.71 times forward earnings, with a PEG ratio of 1.27. The same page also put the dividend yield at 2.71 percent and the beta at 0.25.

Price and setup

The shares closed at USD 160.05 on September 8, 2026, versus an intraday range of USD 159.40 to USD 163.96 and volume of 5.14 million shares. With the 52-week band at USD 145.79 to USD 212.71, the stock is still closer to the lower end than to the peak.